全球寡核苷酸类药物开发现状与趋势

Development Status and Trend Analysis of Oligonucleotide Therapies

目的：从产品开发角度分析寡核苷酸类药物的发展现状和未来趋势。方法：检索科睿唯安（Clarivate analytics）的Cortellis数据库的数据,利用定量分析法和对比分析法对检索结果进行分析。结果：目前已有7种寡核苷酸类药物上市,4种寡核苷酸类药物处于预注册及16种处于临床III期,未来市场上的寡核苷酸类药物将呈现快速增长趋势。此外,寡核苷酸类药物的商业交易也越来越多,目前共发生包括药物开发及商业化许可、专利资产出售以及早期药物研发合作等10余起交易,其中药物开发及商业化许可是最主要的交易模式。结论：虽然寡核苷酸类药物市场尚处于起步阶段,但随着技术的不断发展改进,相信未来有更多的寡核苷酸类药物上市,为癌症及其他疾病的治疗提供新的契机。

Objective： To analyze the development status and trend of Oligonucleotide therapies in the sense of product manufacturing. Methods： Based on the Cortellis database of Clarivate Analytics,this paper analyzed the searching results with utilizing quantitative analysis and comparative analysis methods. Results： Currently,7 Oligonucleotide therapies have been launched into markets,another 4 Oligonucleotide therapies are at registration phase and 16 at Phase III clinical trial. In addition,business deals related to Oligonucleotide therapies are increasing in recent years,including more than 12 deals so far,ranging from drug development,commercial license,and patent assets sales to drug RD cooperation in early phase. As for China,several Oligonucleotide therapies are at clinical stage,and a bright prospect can be expected for Chinese Oligonucleotide therapeutic product markets. Conclusion： Although Oligonucleotide therapies market still at its preliminary stage,however,with the continuous development and improvement of future technology,it is believed that more Oligonucleotide therapies will be launched in the future,providing a new opportunity for the treatment of cancer and other diseases.